Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page
- Check2 days agoChange DetectedThe site’s page interface/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” without any accompanying change to the displayed study record content.SummaryDifference0.0%

- Check9 days agoChange DetectedA new site revision entry v3.5.2 was added and the older revision entry v3.5.0 was removed.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedAdded a site revision label 'Revision: v3.5.0' and removed 'Revision: v3.4.3'.SummaryDifference0.0%

- Check45 days agoChange DetectedEligibility criteria updated to require at least one prior therapy after checkpoint inhibitors and to include relapse, replacing the previous requirement of at least two prior therapies and removing certain transplant/cytotoxic treatment exclusions.SummaryDifference0.3%

- Check74 days agoChange DetectedRevision: v3.4.2 is now displayed; the earlier government funding/operating status notice (Revision: v3.4.1) has been removed. This is an administrative update and does not affect the study details.SummaryDifference0.4%

- Check81 days agoChange DetectedAdded a site-wide notice about potential delays due to government funding and the NIH Clinical Center status. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.